KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Treasury Shares (2017 - 2025)

Historic Treasury Shares for NovoCure (NVCR) over the last 9 years, with Q3 2025 value amounting to $13.6 million.

  • NovoCure's Treasury Shares rose 189.07% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 189.07%. This contributed to the annual value of $12.1 million for FY2024, which is 10757.57% up from last year.
  • Per NovoCure's latest filing, its Treasury Shares stood at $13.6 million for Q3 2025, which was up 189.07% from $13.7 million recorded in Q2 2025.
  • NovoCure's 5-year Treasury Shares high stood at $13.9 million for Q1 2025, and its period low was $4.5 million during Q3 2021.
  • Moreover, its 5-year median value for Treasury Shares was $5.8 million (2023), whereas its average is $8.2 million.
  • In the last 5 years, NovoCure's Treasury Shares tumbled by 280.39% in 2021 and then skyrocketed by 14286.92% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Treasury Shares stood at $4.5 million in 2021, then increased by 20.59% to $5.4 million in 2022, then increased by 8.1% to $5.8 million in 2023, then surged by 107.58% to $12.1 million in 2024, then increased by 12.76% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $13.7 million for Q2 2025, and $13.9 million during Q1 2025.